Should all patients with systemic lupus erythematosus receive cardioprotection with statins?

Abstract

Although the prognosis of patients with systemic lupus erythematosus (SLE) has improved over the past few decades, the increased occurrence of atherosclerotic vascular disease in these patients has become apparent. This Viewpoint discusses the increased risk of cardiovascular disease in patients with SLE, and how levels of risk can be assessed in order to determine the group of SLE patients most suited to preventative therapy with statins.